ImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors
AUSTIN, Texas – ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), an AI-powered biotherapeutics company, today announced the appointment of Jon Lieber to its Board of Directors, effective immediately.
Mr. Lieber brings over 30 years of financial and strategic leadership across the biotechnology and life sciences sectors, with deep expertise in capital markets, investor relations, and corporate development. He currently serves as Chief Financial Officer at Rallybio, a clinical-stage biotechnology company developing therapies for severe and rare diseases. He also brings valuable experience in Nasdaq governance, having served as both a senior executive and board member of publicly traded companies.
“We are pleased to welcome Jon to IPA’s Board of Directors during this transformative period for the Company,” said Dr. Jennifer Bath, CEO of ImmunoPrecise. “Jon brings the rare and highly valuable combination of Nasdaq board governance and senior executive experience—critical as we navigate commercialization and strategic growth. His deep understanding of capital markets and proven success guiding innovation-driven companies aligns well with our strategy to expand adoption of our LENSai and HYFT® platforms, and to position IPA at the forefront of AI-powered drug discovery.”
Prior to Rallybio, Mr. Lieber was CFO at Applied Genetic Technologies Corporation (AGTC), a publicly traded gene therapy company, where he led all capital-raising efforts and oversaw finance, human resources, investor relations, and IT. He has also held senior leadership roles at Danforth Advisors, Histogenics, Repligen, Xcellerex (acquired by GE Healthcare), and Altus Pharmaceuticals. Earlier in his career, he worked in investment banking at Salomon Brothers / Salomon Smith Barney and SG Cowen.
Mr. Lieber currently serves on the Board of Directors of Salarius Pharmaceuticals, where he is a member of both the Audit Committee and the Nominating and Governance Committee, further underscoring his depth of experience in Nasdaq board governance.
“I’m excited to join IPA’s Board at such a pivotal time,” said Mr. Lieber. “The Company’s ability to integrate in silico discovery with translational biology sets it apart in a rapidly evolving biotherapeutics landscape. I look forward to supporting IPA’s continued momentum and strategic execution.”
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise (NASDAQ: IPA) is a global leader in AI-powered biotherapeutic discovery and development. Its proprietary HYFT technology and LENSai platform enable first-principles-based drug design, delivering validated therapeutic candidates across modalities and therapeutic areas. IPA partners with 19 of the top 20 pharmaceutical companies and is advancing next-generation biologics through data-driven, human-relevant models.